Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292016 · ClinicalTrials.gov registry record · Phase 2
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03292016 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 8 participants.
The verdict
NCT03292016, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated by "OFF" episodes.
Interventions
- DRUG APL-130277
- DRUG APO-go
- DRUG Apokyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-08-22 |
| Est. Completion | 2019-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03292016
The ClinicalTrials.gov registry entry for NCT03292016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which APL-130277 is the first listed.
NCT03292016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03292016 about?
NCT03292016 is a clinical study titled "A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes". A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated by "OFF" episodes.
What is the current status of trial NCT03292016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2017-08-22. Estimated completion is 2019-03-05.
What interventions are being tested in trial NCT03292016?
The interventions under investigation include: APL-130277 (DRUG), APO-go (DRUG), Apokyn (DRUG).
Who is sponsoring clinical trial NCT03292016?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.